Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Loriot MA, Masskouri F, Carni P, Le Malicot K, Seitz JF, Michel P, Legoux JL, Bouché O, André T, Faroux R, Delaloge S, Malka D, Guigay J, Thariat J, Thomas F, Barin-Le-Guellec C, Ciccolini J, Boyer JC, Étienne-Grimaldi MC.

Bull Cancer. 2019 Jun 25. pii: S0007-4551(19)30225-5. doi: 10.1016/j.bulcan.2019.04.013. [Epub ahead of print] French.

PMID:
31253356
2.

[Acute carpal tunnel syndrome caused by a thrombosis of a persistent median artery: 2 case reports].

Avenel M, Miranda S, Benhamou Y, Michelin P, Boyer JC, Lévesque H, Armengol G.

Rev Med Interne. 2019 Jul;40(7):453-456. doi: 10.1016/j.revmed.2019.04.002. Epub 2019 Apr 28. French.

PMID:
31040049
3.

Review: Endogenously Produced Volatiles for In Vitro Toxicity Testing Using Cell Lines.

Winters BR, Pleil JD, Boyer JC, Nylander-French LA, Wallace MAG, Madden MC.

Appl In Vitro Toxicol. 2018 Jun 1;4(2):129-138. doi: 10.1089/aivt.2017.0038. Review.

4.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Sep;106(3):585-595. doi: 10.1002/cpt.1404. Epub 2019 Apr 10.

PMID:
30786012
5.

How can we best monitor 5-FU administration to maximize benefit to risk ratio?

Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, Bardou M, Schmitt A.

Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1303-1313. doi: 10.1080/17425255.2018.1550484. Epub 2018 Nov 23. Review.

6.

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A.

Bull Cancer. 2018 Sep;105(9):790-803. doi: 10.1016/j.bulcan.2018.06.008. Epub 2018 Aug 10. Review. French.

7.

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

8.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
9.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

10.

Cancer genomics guide clinical practice in personalized medicine.

Lehmann-Che J, Poirot B, Boyer JC, Evrard A.

Therapie. 2017 Sep;72(4):439-451. doi: 10.1016/j.therap.2016.09.015. Epub 2017 Jan 30. Review.

PMID:
28258721
11.

Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; French National Network of Pharmacogenetics (RNPGx).

Therapie. 2017 Apr;72(2):185-192. doi: 10.1016/j.therap.2016.09.014. Epub 2017 Jan 30. Review.

PMID:
28237406
12.

La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision.

Lehmann-Che J, Poirot B, Boyer JC, Evrard A.

Therapie. 2017 Apr;72(2):217-230. doi: 10.1016/j.therap.2016.09.009. Epub 2017 Jan 3. French. No abstract available.

PMID:
28162246
13.

Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).

Picard N, Boyer JC, Etienne-Grimaldi MC, Barin-Le Guellec C, Thomas F, Loriot MA; Réseau national de pharmacogénétique (RNPGx).

Therapie. 2017 Apr;72(2):175-183. doi: 10.1016/j.therap.2016.09.007. Epub 2017 Jan 3. French. No abstract available.

PMID:
28153355
14.

The Impact of Environmental and Endogenous Damage on Somatic Mutation Load in Human Skin Fibroblasts.

Saini N, Roberts SA, Klimczak LJ, Chan K, Grimm SA, Dai S, Fargo DC, Boyer JC, Kaufmann WK, Taylor JA, Lee E, Cortes-Ciriano I, Park PJ, Schurman SH, Malc EP, Mieczkowski PA, Gordenin DA.

PLoS Genet. 2016 Oct 27;12(10):e1006385. doi: 10.1371/journal.pgen.1006385. eCollection 2016 Oct.

15.

Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.

Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, Bourgaux JF, Prudhomme M, Philippe C, Bravo S, Boyer JC, Canterel-Thouennon L, Taylor GR, Hsu A, Pascussi JM, Hollande F, Pannequin J.

Gut. 2017 Oct;66(10):1802-1810. doi: 10.1136/gutjnl-2016-311447. Epub 2016 Jul 25.

16.

Nod Factor Effects on Root Hair-Specific Transcriptome of Medicago truncatula: Focus on Plasma Membrane Transport Systems and Reactive Oxygen Species Networks.

Damiani I, Drain A, Guichard M, Balzergue S, Boscari A, Boyer JC, Brunaud V, Cottaz S, Rancurel C, Da Rocha M, Fizames C, Fort S, Gaillard I, Maillol V, Danchin EG, Rouached H, Samain E, Su YH, Thouin J, Touraine B, Puppo A, Frachisse JM, Pauly N, Sentenac H.

Front Plant Sci. 2016 Jun 7;7:794. doi: 10.3389/fpls.2016.00794. eCollection 2016.

17.

Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.

Mbatchi LC, Robert J, Ychou M, Boyer JC, Del Rio M, Gassiot M, Thomas F, Tubiana N, Evrard A.

Clin Pharmacokinet. 2016 Sep;55(9):1145-57. doi: 10.1007/s40262-016-0392-5.

PMID:
27116457
18.

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

Mbatchi LC, Schmitt A, Thomas F, Cazaubon Y, Robert J, Lumbroso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A.

Pharmacogenomics. 2015;16(13):1439-50. doi: 10.2217/pgs.15.84. Epub 2015 Aug 12.

PMID:
26267044
19.

The Arabidopsis root stele transporter NPF2.3 contributes to nitrate translocation to shoots under salt stress.

Taochy C, Gaillard I, Ipotesi E, Oomen R, Leonhardt N, Zimmermann S, Peltier JB, Szponarski W, Simonneau T, Sentenac H, Gibrat R, Boyer JC.

Plant J. 2015 Aug;83(3):466-79. doi: 10.1111/tpj.12901. Epub 2015 Jul 2.

20.

UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C; Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer); French Réseau National de Pharmacogénétique Hospitalière (RNPGx).

Fundam Clin Pharmacol. 2015 Jun;29(3):219-37. doi: 10.1111/fcp.12117. Epub 2015 May 4.

PMID:
25817555
21.

DNA methylation modifies urine biomarker levels in 1,6-hexamethylene diisocyanate exposed workers: a pilot study.

Nylander-French LA, Wu MC, French JE, Boyer JC, Smeester L, Sanders AP, Fry RC.

Toxicol Lett. 2014 Dec 1;231(2):217-26. doi: 10.1016/j.toxlet.2014.10.024. Epub 2014 Oct 22.

PMID:
25445006
22.

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

Boyer JC, Etienne-Grimaldi MC, Thomas F, Quaranta S, Picard N, Loriot MA, Poncet D, Gagnieu MC, Ged C, Broly F, Le Morvan V, Bouquié R, Gaub MP, Philibert L, Ghiringhelli F, Le Guellec C.

Bull Cancer. 2014 Jun;101(6):533-53. doi: 10.1684/bdc.2014.1933. Review. French.

PMID:
24977443
23.

Unilateral subarachnoid and intravitreous FLAIR hyperintensities after gadolinium-enhanced MRI.

Renard D, Moesch C, Boyer JC, Freitag C, Thouvenot E.

Acta Neurol Belg. 2015 Mar;115(1):89-90. doi: 10.1007/s13760-014-0321-z. Epub 2014 Jun 13. No abstract available.

PMID:
24925257
24.

A unified nomenclature of NITRATE TRANSPORTER 1/PEPTIDE TRANSPORTER family members in plants.

Léran S, Varala K, Boyer JC, Chiurazzi M, Crawford N, Daniel-Vedele F, David L, Dickstein R, Fernandez E, Forde B, Gassmann W, Geiger D, Gojon A, Gong JM, Halkier BA, Harris JM, Hedrich R, Limami AM, Rentsch D, Seo M, Tsay YF, Zhang M, Coruzzi G, Lacombe B.

Trends Plant Sci. 2014 Jan;19(1):5-9. doi: 10.1016/j.tplants.2013.08.008. Epub 2013 Sep 18.

PMID:
24055139
25.

A UV-blocking polymer shell prevents one-photon photoreactions while allowing multi-photon processes in encapsulated upconverting nanoparticles.

Wu T, Barker M, Arafeh KM, Boyer JC, Carling CJ, Branda NR.

Angew Chem Int Ed Engl. 2013 Oct 11;52(42):11106-9. doi: 10.1002/anie.201305253. Epub 2013 Aug 23.

PMID:
24038865
26.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group.

PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

27.

Lexical fields of predictive and personalized medicine.

Mathieu T, Bermont L, Boyer JC, Versuyft C, Evrard A, Cuvelier I, Couderc R, Peoc'h K; Working Group of the Société française de biologie clinique (SFBC) “ Pharmacogénétique et médecine predictive”.

Drug Metabol Drug Interact. 2013;28(2):125-32. doi: 10.1515/dmdi-2013-0024. Review.

PMID:
23740683
28.

[Lexical fields of predictive and personalized medicine].

Mathieu T, Bermont L, Boyer JC, Versuyft C, Evrard A, Cuvelier I, Couderc R, Peoc'h K.

Ann Biol Clin (Paris). 2012 Nov-Dec;70(6):651-8. doi: 10.1684/abc.2012.0767. Review. French.

29.

Near infrared light triggered release of biomacromolecules from hydrogels loaded with upconversion nanoparticles.

Yan B, Boyer JC, Habault D, Branda NR, Zhao Y.

J Am Chem Soc. 2012 Oct 10;134(40):16558-61. doi: 10.1021/ja308876j. Epub 2012 Sep 28.

PMID:
23013429
30.

Multimodal fluorescence modulation using molecular photoswitches and upconverting nanoparticles.

Carling CJ, Boyer JC, Branda NR.

Org Biomol Chem. 2012 Aug 14;10(30):6159-68. doi: 10.1039/c2ob25368b. Epub 2012 Apr 19.

PMID:
22514112
31.

Photomodulation of fluorescent upconverting nanoparticle markers in live organisms by using molecular switches.

Boyer JC, Carling CJ, Chua SY, Wilson D, Johnsen B, Baillie D, Branda NR.

Chemistry. 2012 Mar 12;18(11):3122-6. doi: 10.1002/chem.201103767. Epub 2012 Feb 16. No abstract available.

PMID:
22344816
32.

Near-infrared light-triggered dissociation of block copolymer micelles using upconverting nanoparticles.

Yan B, Boyer JC, Branda NR, Zhao Y.

J Am Chem Soc. 2011 Dec 14;133(49):19714-7. doi: 10.1021/ja209793b. Epub 2011 Nov 18.

PMID:
22082025
33.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.

J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

34.

[Interprofessional cooperation, a new mode of regulation?].

Boyer JC.

Soins. 2010 Dec;(751):51-2. French.

PMID:
21298946
35.

Two-way photoswitching using one type of near-infrared light, upconverting nanoparticles, and changing only the light intensity.

Boyer JC, Carling CJ, Gates BD, Branda NR.

J Am Chem Soc. 2010 Nov 10;132(44):15766-72. doi: 10.1021/ja107184z.

PMID:
20949969
36.

Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.

Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Mousseau M, Pinguet F, Floquet A, Billaud EM, Durdux C, Le Guellec C, Mazières J, Lafont T, Ollivier F, Concordet D, Chatelut E.

J Clin Oncol. 2010 Oct 20;28(30):4568-74. doi: 10.1200/JCO.2010.29.3597. Epub 2010 Sep 20.

PMID:
20855828
37.

Absolute quantum yield measurements of colloidal NaYF4: Er3+, Yb3+ upconverting nanoparticles.

Boyer JC, van Veggel FC.

Nanoscale. 2010 Aug;2(8):1417-9. doi: 10.1039/c0nr00253d. Epub 2010 May 29.

PMID:
20820726
38.

Facile ligand-exchange with polyvinylpyrrolidone and subsequent silica coating of hydrophobic upconverting beta-NaYF(4):Yb(3+)/Er(3+) nanoparticles.

Johnson NJ, Sangeetha NM, Boyer JC, van Veggel FC.

Nanoscale. 2010 May;2(5):771-7. doi: 10.1039/b9nr00379g. Epub 2010 Mar 4.

PMID:
20648323
39.

Reversal of bupivacaine-induced cardiac electrophysiologic changes by two lipid emulsions in anesthetized and mechanically ventilated piglets.

Candela D, Louart G, Bousquet PJ, Muller L, Nguyen M, Boyer JC, Peray PA, Goret L, Ripart J, Lefrant JY, de La Coussaye JE.

Anesth Analg. 2010 May 1;110(5):1473-9. doi: 10.1213/ANE.0b013e3181d53c8d.

PMID:
20418308
40.

[Management of sexual violence perpetrators, legal clarification].

Boyer JC.

Soins Psychiatr. 2010 Mar-Apr;(267):27-8. French. No abstract available.

PMID:
20402155
41.

Remote-control photorelease of caged compounds using near-infrared light and upconverting nanoparticles.

Carling CJ, Nourmohammadian F, Boyer JC, Branda NR.

Angew Chem Int Ed Engl. 2010 May 17;49(22):3782-5. doi: 10.1002/anie.201000611. No abstract available.

PMID:
20394093
42.

[Lactic acidosis after voluntary intoxication with valproic acid].

Deras P, Gignon L, Toumi M, Louart G, Muller L, Boyer JC, Lefrant JY.

Ann Fr Anesth Reanim. 2010 Jan;29(1):63-4. doi: 10.1016/j.annfar.2009.12.011. Epub 2010 Jan 15. French. No abstract available.

PMID:
20080012
43.

High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.

Raynal C, Ciccolini J, Mercier C, Boyer JC, Polge A, Lallemant B, Mouzat K, Lumbroso S, Brouillet JP, Evrard A.

Ther Drug Monit. 2010 Feb;32(1):53-60. doi: 10.1097/FTD.0b013e3181c77c1b.

PMID:
20010457
44.

Hard proof of the NaYF(4)/NaGdF(4) nanocrystal core/shell structure.

Abel KA, Boyer JC, van Veggel FC.

J Am Chem Soc. 2009 Oct 21;131(41):14644-5. doi: 10.1021/ja906971y. Erratum in: J Am Chem Soc. 2010 Apr 21;132(15):5533.

PMID:
19824725
45.

Surface modification of upconverting NaYF4 nanoparticles with PEG-phosphate ligands for NIR (800 nm) biolabeling within the biological window.

Boyer JC, Manseau MP, Murray JI, van Veggel FC.

Langmuir. 2010 Jan 19;26(2):1157-64. doi: 10.1021/la902260j.

PMID:
19810725
46.

Remote-control photoswitching using NIR light.

Carling CJ, Boyer JC, Branda NR.

J Am Chem Soc. 2009 Aug 12;131(31):10838-9. doi: 10.1021/ja904746s.

PMID:
19722663
47.

MLH1 mediates PARP-dependent cell death in response to the methylating agent N-methyl-N-nitrosourea.

McDaid JR, Loughery J, Dunne P, Boyer JC, Downes CS, Farber RA, Walsh CP.

Br J Cancer. 2009 Aug 4;101(3):441-51. doi: 10.1038/sj.bjc.6605186. Epub 2009 Jul 21. Erratum in: Br J Cancer. 2010 Mar 16;102(6):1080.

48.

A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study.

Cuvillon P, Nouvellon E, Ripart J, Boyer JC, Dehour L, Mahamat A, L'hermite J, Boisson C, Vialles N, Lefrant JY, de La Coussaye JE.

Anesth Analg. 2009 Feb;108(2):641-9. doi: 10.1213/ane.0b013e31819237f8.

PMID:
19151302
49.

Sequence-dependent effect of interruptions on microsatellite mutation rate in mismatch repair-deficient human cells.

Boyer JC, Hawk JD, Stefanovic L, Farber RA.

Mutat Res. 2008 Apr 2;640(1-2):89-96. doi: 10.1016/j.mrfmmm.2007.12.005. Epub 2007 Dec 23.

PMID:
18242644
50.

[Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects].

Allorge D, Beaune PH, Becquemont L, Bessard G, Bezieau S, Boisdron-Celle M, Boyer JC, Broly F, Dhaneens CM, Fonrose X, Gagnieu MC, Gamelin E, Gozé C, Jacqz-Aigrain E, Loric S, Loriot MA, Marquet P, Morel A, Namour B, Paintaud G, Peoc'h K, Picard N, Watier H, Verstuyft C.

Ann Pharm Fr. 2007 Nov;65(6):371-81. Review. French.

PMID:
18079669

Supplemental Content

Loading ...
Support Center